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REVIEW
Nonsurgical therapy for hydrocephalus: 
a comprehensive and critical review
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Abstract 
Pharmacological interventions have been tested experimentally and clinically to prevent hydrocephalus and avoid 
the need for shunting beginning in the 1950s. Clinical trials of varied quality have not demonstrated lasting and con-
vincing protective effects through manipulation of cerebrospinal fluid production, diuresis, blood clot fibrinolysis, or 
manipulation of fibrosis in the subarachnoid compartment, although there remains some promise in the latter areas. 
Acetazolamide bolus seems to be useful for predicting shunt response in adults with hydrocephalus. Neuroprotec-
tion in the situation of established hydrocephalus has been tested experimentally beginning more recently. Therapies 
designed to modify blood flow or pulsation, reduce inflammation, reduce oxidative damage, or protect neurons are 
so far of limited success; more experimental work is needed in these areas. As has been recommended for preclinical 
studies in stroke and brain trauma, stringent conditions should be met for preclinical studies in hydrocephalus.
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Background
Hydrocephalus was defined by Rekate as “an active dis-
tension of the ventricular system of the brain resulting 
from inadequate passage of cerebrospinal fluid (CSF) 
from its point of production within the cerebral ventri-
cles to its point of absorption into the systemic circula-
tion” [1]. Although all do not accept this definition, it has 
helped to guide an expert consensus opinion that most 
forms of hydrocephalus can be classified according to 
an identifiable anatomical site of CSF flow obstruction 
or impairment [2]. There is currently no definitive cure. 
Most patients are managed by shunting using a silicone 
tube and valve system, where CSF is diverted from the 
cerebral ventricles to another body site [3]. Treatment 
by shunting is associated with frequent complications, 
particularly obstruction and infection in young infants, 
which add to morbidity and mortality. In a large pop-
ulation-based analysis in California (1990–2000), the 
cumulative 5-year complication rate was approximately 
48 % in children and 27 % in adults [4]. A recent pediatric 
study showed a 33 % shunt failure in 3 years [5]. Surgi-
cal alternatives to ventriculo-peritoneal shunting, such as 
endoscopic third ventriculostomy (ETV), have become 
popular. In controlled trials, ETV has reasonable efficacy 
in pediatric hydrocephalus particularly for aqueduct ste-
nosis [6, 7]. ETV requires more robust evidence for rou-
tine use in adult normal pressure hydrocephalus (NPH) 
[8]. Lumboperitoneal shunting also shows some promise 
in NPH [9].
Because of the potential for complications, neurosur-
geons may be hesitant to operate on young (especially 
preterm) infants with hydrocephalus. However, enlarg-
ing ventricles and delayed shunting might be associ-
ated with progressive brain damage [10]. For more than 
six decades, researchers have been trying to develop 
nonsurgical means for management of hydrocephalus. 
Three main categories of treatment have been explored 
in animal models and, in some situations, hydrocephalic 
patients. These include reducing CSF production, reduc-
ing the inflammatory and fibrotic processes that occur 
following brain hemorrhage or meningitis, and “protec-
tion” of brain cells and axons after ventriculomegaly has 
developed. The latter is envisioned as a supplemental 
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intervention that would allow a safe delay in surgical 
shunting of hydrocephalus.
The purpose of this review is to summarize and evalu-
ate research concerning pharmacological therapies for 
hydrocephalus. The goal is to be comprehensive with an 
explanation of the rationale in animal experiments and a 
careful consideration of the earliest and the most defini-
tive clinical trials. The review is organized in respect to 
the pathophysiologic factors involved in the develop-
ment of hydrocephalus, specifically CSF production, CSF 
pathway obstruction (inflammation, fibrosis), and brain 
damage. Because some aspects of the pathogenesis of 
hydrocephalic brain damage are very similar to those that 
occur in cerebral ischemia (stroke) and brain trauma, 
evaluation of preclinical research should be similarly 
robust. Therefore, the quality of preclinical research stud-
ies related to brain protection will be judged using guide-
lines originally proposed by the Stroke Therapy Academic 
Industry Roundtable group [11, 12] and adopted by brain 
trauma investigators [13].
Methods
The senior author beginning c2000 has collected lit-
erature related to this topic. This was supplemented 
by structured searches in PubMed and GoogleScholar 
using the main term “hydrocephalus” along with key 
words “anti-inflammatory, diuretic, drug therapy, drug 
effects, fibrinolysis, inhibitor, neuroprotective, osmotic, 
pharmacology, randomized, steroid”. Titles and abstracts 
were reviewed to ensure that the main topic was hydro-
cephalus. There is considerable overlap with the lit-
erature concerning brain or subarachnoid hemorrhage; 
only papers related to CSF flow or ventricular enlarge-
ment are addressed here. Relevant manuscripts were 
read in detail, and additional publications that had not 
been identified in the search were sought from the bib-
liographies (especially pre-1960, a period when works 
are less comprehensively recorded in PubMed). There 
were no time limits imposed; historical context is con-
sidered important. Considering the paucity of modern 
randomized trials in humans, this review is not meant 
as a meta-analysis; there are no specific exclusion crite-
ria. In general, the sections are organized to separate the 
historical and experimental background from the pediat-
ric and adult clinical studies, although this is not always 
possible. Treatments for shunt infection are not included. 
Detailed consideration of the pharmacodynamics of the 
drugs is beyond the scope of the review, although they 
will be mentioned when relevant to the interpretation of 
selected experiments. Some of the pharmacologic factors 
were described in a previous review [14]; details of the 
pharmacodynamics are beyond the scope of this review.
Results
Cerebrospinal fluid production and brain fluids
Readers are referred to other reviews for comprehensive 
considerations of choroid plexus function including CSF 
production [15–17], flow of brain fluids through intercel-
lular and paravascular compartments [18–21], and CSF 
absorption [22, 23].
Osmotic agents and CSF pressure
One of the first pharmacologic attempts to manage 
hydrocephalus was by Marriott who, in 1924, reported 
that the diuretic agent theobromin sodio salicylate stabi-
lized the head size of six infants with progressive hydro-
cephalus [24]. In the 1950s and early 1960s, when shunt 
therapy was emerging, drug therapies for hydrocephalus 
were directed at reducing CSF production or dehydrating 
the brain by diuresis. Typically, an appropriate physiolog-
ical response in normal animals was sufficient rationale 
for testing of a drug in hydrocephalic humans. An excel-
lent pharmacologic review of these agents was previously 
published [14].
Isosorbide, a dihydric alcohol derived from sorbitol 
that functions as an osmotic diuretic, is the best studied 
in hydrocephalus. Oral isosorbide transiently reduced 
the CSF pressure in healthy adult dogs [25]. A similar 
reduction in ventricular CSF pressure was demonstrated 
in 14 hydrocephalic children, although a rebound above 
the baseline was reported in 5/10 children who received 
multiple doses [26]. In what were described as pre-
liminary experiments, 45 hydrocephalic patients (new-
born to 62 years, median age 1 month) received 1–3 g/
kg orally up to six times per day for 1–54 days (median 
4  days) and were monitored for benefits defined as 
reduced CSF pressure or head size; 53/97 treatment epi-
sodes had some benefit and 26/97 had adverse effects 
[27–29]. Subsequently, Lorber conducted uncontrolled 
trials of isosorbide in infants with many forms of hydro-
cephalus; he eventually concluded that it was an effective 
adjunct for temporarily controlling intracranial pressure 
(ICP) prior to shunting, but not a replacement for sur-
gery except perhaps in a minority of infants with mye-
lomeningocele [30–33]. A controlled study of children 
with myelomeningocele two decades later compared 
14 treated with isosorbide and 17 managed without the 
drug. Although isosorbide allowed delay of the surgical 
closure, there was no difference in need for shunting; fur-
thermore, side effects led the authors to conclude that it 
has no role in management of these children [34].
Glycerol, a trivalent sugar alcohol, was known as a diu-
retic agent since the early 1900s [35]. As an oral osmotic 
agent, it was shown to reduce intracranial pressure in 
adults with brain tumors and was suggested as a possible 
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agent for managing hydrocephalus [36]. However, a few 
small, uncontrolled trials did not support its use. Glyc-
erol had no effect in four premature infants with post-
hemorrhagic hydrocephalus [37] and did not alleviate 
hydrocephalus in adults with metastatic brain cancer 
[38]. Although not a therapeutic effect, NPH patients 
who displayed an increase in cerebral blood flow (CBF) 
after glycerol administration tended to have a favorable 
response to shunt surgery [39]. Other sugar alcohols, 
mannitol and erythritol, transiently decreased ICP in 
adult hydrocephalic dogs following intravenous admin-
istration [40]. Although used widely for temporary man-
agement of elevated ICP in  situations of brain swelling, 
mannitol has seldom been used except in adults with 
acute hydrocephalus caused by intracerebral hemorrhage 
[41]. In two chronically hydrocephalic children manni-
tol or urea transiently reduced ICP, however there was a 
rebound above baseline pressure [26].
Interference with CSF production
Because CSF dynamics are affected in obstructive forms 
of hydrocephalus, beginning in the 1950s and 1960s 
researchers have sought to treat hydrocephalus by reduc-
ing CSF production.
Acetazolamide
Acetazolamide, a carbonic anhydrase inhibitor, decreases 
CSF flow and ICP in rabbits and cats [42–44]. This was 
initially thought to be a diuretic and natriuretic effect 
through inhibition of carbonic anhydrase in the kid-
neys. However, later it was determined that choroid 
plexus has high levels of carbonic anhydrase and aceta-
zolamide causes direct inhibition of CSF production. 
More recently, acetazolamide was also shown to inhibit 
aquaporin-mediated water conductance through several 
molecular pathways [45]. Acetazolamide was shown to 
reduce the lateral ventricle size of young adult rats, 1 day 
following injection of thrombin into the ventricle [46, 
47]; however, ventricular enlargement was minimal in 
controls and the survival time too brief to be meaningful. 
Veterinary use of acetazolamide in hydrocephalus dogs is 
not beneficial [48].
Acetazolamide in hydrocephalic children
In trials beginning 1956, Elvidge and coworkers found 
that oral acetazolamide improved the clinical condition 
of a hydrocephalic child who was suffering from numer-
ous shunt complications; vasopressin had no beneficial 
effect [49]. Benefit was also reported anecdotally and in 
small trials by others [50–55]. However, detailed physio-
logic studies on humans showed inconsistent reductions 
in CSF production [56]. By the late 1960s, it had become 
apparent that the therapeutic effect of acetazolamide in 
hydrocephalic children was negligible [57, 58].
Acetazolamide in hydrocephalic adults
Despite failed use in children, acetazolamide was pro-
posed as an alternative to shunting for adults with NPH 
[59]. Although there was no persisting effect on ICP, the 
transient reduction in ICP following an acetazolamide 
bolus was shown to be predictive of good response to 
shunting in NPH patients [60]. Normal people have a 
transient increase in CBF (measured by first-pass radi-
onuclide angiography) in response to a bolus; people 
with NPH have an impaired cerebrovascular response 
[61] and a blunted response was reported to be pre-
dictive of good response to shunting [62]. The poor 
increase in CBF following acetazolamide is thought to 
indicate a low capacity for vasodilation in the hydroce-
phalic brain, possibly due to compression of blood ves-
sels [63]. In 5/8 NPH patients, administration of oral 
acetazolamide (125–375 mg/day) was associated with a 
decrease in the periventricular hyperintensities seen on 
magnetic resonance (MR) imaging [64] and an increase 
in CBF measured using MR arterial spin labeling [65]. 
There remains limited interest in the use of acetazola-
mide for treatment of idiopathic intracranial hyperten-
sion [66, 67].
Furosemide/acetazolamide combination in hydrocephalic 
children
Furosemide is a diuretic agent that inhibits the Na–K–
2Cl symporter located in the distal tubules of kidney. 
Furosemide has minimal effect on CSF formation in 
healthy cats and dogs [44, 68], but CSF formation was 
reduced in preterm rabbits and in adult rabbits, albeit 
much less potently than acetazolamide [69, 70]. Vinas 
mentioned use of furosemide in management of a hydro-
cephalic child [71]. Chaplin and coworkers claimed to 
have arrested the progression of hydrocephalus in 4/7 
infants with posthemorrhagic hydrocephalus by repeated 
CSF drainage and administration of oral acetazolamide 
and furosemide [72]. Shinnar et  al. [73] gave the drug 
combination to 49 hydrocephalic children; they reported 
a 57  % success rate (avoidance of shunt) in non-mye-
lomeningocele patients but only 26 % success in infants 
with myelomeningocele. An uncontrolled trial conducted 
from 1982–86 also hinted at benefit [74, 75]. A rand-
omized control trial of the acetazolamide/furosemide 
combination for premature infants with posthemorrhagic 
ventricular dilatation was conducted from 1992–96. 
Unfortunately it failed to show benefit [76–78]. This trial 
was criticized for its failure to prove a solid rationale and 
safety background before starting [79].
Page 4 of 20Del Bigio and Di Curzio  Fluids Barriers CNS  (2016) 13:3 
Other ion channel blockers
Other drugs that block ion channels have been tested 
in small numbers of hydrocephalic patients. Digoxin, 
an inhibitor of Na–K–ATPase, reduces CSF produc-
tion in humans at doses that are not cardiotoxic [80]. 
Digoxin was reported to reduce CSF production in three 
hydrocephalic children [81], but in three hydrocephalic 
infants it failed to prevent enlargement of the head [82]. 
Triamterene is a diuretic drug that blocks the epithelial 
sodium channel (ENaC). Three adults (age 25–76 years) 
with chronic hydrocephalus had resolution of symptoms 
during a 3–12  week treatment with triamterene [83]. 
Antagonists to the transient receptor potential vanil-
loid 4 (TRPV4), a gated divalent cation channel highly 
expressed by choroid plexus [84], have also been pro-
posed as a treatment for hydrocephalus [85], but there 
are no published data supporting the concept.
Glucocorticoids
Steroids, in particular the glucocorticoids, have been 
used for decades with variable benefit in a range of 
neurological disorders associated with raised ICP. In 
healthy rabbits, betamethasone reduced CSF produc-
tion after 5  days [86]. In normal dogs and in dogs with 
kaolin-induced hydrocephalus, intravenous dexametha-
sone or methylprednisolone caused a 40 % reduction in 
CSF flow for approximately 6  h, in the absence of diu-
resis or changes in blood pressure [87, 88]. The effect is 
through specific binding to the mineralocorticoid recep-
tor (NR3C2; nuclear receptor subfamily 3 group C mem-
ber 2) on choroid plexus epithelial cells, with subsequent 
regulation of several functions [89]. In 13 shunted hydro-
cephalic children with symptomatic slit ventricle syn-
drome, dexamethasone was associated with temporary 
relief of symptoms, although 9/13 required subsequent 
surgical intervention [90]. In the context of hydrocepha-
lus, corticosteroids have also been used as a possible way 
to reduce the fibrosis in the subarachnoid compartment 
(see below).
Choroid plexus destruction
Surgical ablation of the choroid plexus as a means to 
control hydrocephalus was proposed by Dandy [91]. 
Using modern surgical techniques in combination with 
endoscopic third ventriculostomy, Warf has shown that 
this approach can be successful in selected cases less 
than 1-year age [92]. Non-surgical means of destroy-
ing the choroid plexus have also been attempted. In 
the 1970s, several groups of investigators injected 
radioactive agents into the ventricles of cats and dogs 
with kaolin-induced hydrocephalus. Gold-198 in col-
loidal form caused necrosis of the choroid plexus and 
reduced CSF production [93–95]. Rhenium-188 [96] 
and technetium-99  m [97] were not effective in similar 
model systems. Intraventricular injection of radioactive 
chromic phosphate-phosphorus-32 into four hydroce-
phalic infants was reported to arrest head growth, but 
long-term results were not presented [98]. Likely due to 
the high potential for side effects, others have not pur-
sued this approach.
Destruction of choroid plexus by ricin toxin-conjugated 
to antibodies that bind to the epithelial cells was tested 
in culture and was proposed as a means for managing 
hydrocephalus [99, 100]. However, there are no published 
experiments using animal models.
Summary of CSF modulation for managing hydrocephalus
Reduction of brain water with osmotic agents and inhi-
bition of choroid plexus ion channels provide transient 
reductions in the ICP or CSF pressure of hydrocephalic 
children and adults. However, no lasting effects have 
been demonstrated in published clinical trials, although 
recent work in NPH suggests that there might be a 
role for acetazolamide at least as a test agent to predict 
response to shunting [101]. Considering that the half-life 
of acetazolamide is 4  h, divided dosing regimens might 
be needed to achieve optimal effectiveness. Conceivably, 
highly selective inhibition of choroid plexus ion channels 
that are not present in other epithelia (e.g. kidney) might 
be associated with fewer side effects and might work 
in  situations where obstructions to CSF flow are only 
partial. It will likely be difficult to avoid toxicity in non-
surgical ablation approaches.
Cerebrospinal fluid pathway modulation
CSF pathway inflammation and fibrosis
One of the general features of hydrocephalus is a rela-
tive restriction of CSF movement (bulk flow or pulsatile 
movement) along its anatomical route [2]. Circumstances 
that can lead to restrictions include intraventricular hem-
orrhage, subarachnoid hemorrhage, or infection (e.g. 
meningitis); all are associated with secondary inflam-
mation and fibrosis in the CSF pathways, especially the 
subarachnoid compartment [102]. In children, intra-
ventricular hemorrhage and bacterial meningitis are 
associated with meningeal fibrosis, which obliterates 
the subarachnoid space [103, 104]. In adults with suba-
rachnoid hemorrhage, inflammation occurs within the 
arachnoid villi during the first week and is followed by 
proliferation of arachnoid cap cells [105] and collagen 
production [106]. Enzymatic dissolution of the intra-
ventricular or subarachnoid blood collections, interfer-
ence with the inflammatory process, and interference 
with the production of extracellular matrix molecules are 
approaches that have been explored as ways to reduce the 
likelihood of developing hydrocephalus.
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Enzymatic dissolution of intracranial blood collections 
in animals
Tissue plasminogen activator (tPA) is a serine proteinase 
that binds to fibrin in clotted blood and converts plasmi-
nogen to plasmin, thereby initiating fibrinolysis and dis-
solution of the blood clot. Urokinase (or urokinase-type 
plasminogen activator/uPA) is a proteolytic enzyme pre-
sent in urine, blood, and extracellular matrix; it is also 
capable of activating plasminogen and it can digest extra-
cellular matrix proteins [107]. Streptokinase is a bacte-
rial enzyme capable of cleaving plasminogen, although 
it is less discriminate and can activate plasminogen that 
is not associated with blood clots [108]. Thrombolytic 
therapies for ischemic stroke were first pursued in the 
1970s; intravascular recombinant tPA is an important 
intervention for some adults with early ischemic stroke 
[109]. However, tPA can have adverse effects in the brain 
parenchyma [110].
Experimental brain hemorrhage models have been used 
to determine if these agents can accelerate clot lysis and 
reduce the subsequent development of hydrocephalus. 
In dogs with experimental subarachnoid hemorrhage, 
intrathecal urokinase reduced fibrosis in the intracranial 
subarachnoid compartment at 3  weeks and 3  months 
[111]. The number of subarachnoid macrophages was 
greater following urokinase than in control dogs [112]. 
In dogs with experimental intraventricular hemor-
rhage (IVH), urokinase effectively lysed the blood clot in 
3–6 days (vs. 38–65 days in controls); only 2/10 treated 
dogs (compared to 9/10 control dogs) developed progres-
sive hydrocephalus [113]. Cats that were treated with an 
infusion of intrathecal tPA 1 day after the intracisternal 
blood injection did not develop hydrocephalus at 7 days 
[114]. Pigs with experimental IVH had more rapid reso-
lution of the blood clot and reduction in the ventricle size 
at 1  week after treatment with tPA, although the con-
trol animals had reached comparable ventricle size by 
6 weeks [115, 116]. In the collagenase model of intracer-
ebral hemorrhage in young adult rats, infusion of uroki-
nase or tPA into the lateral ventricle for 1 h beginning 3 h 
after collagenase was associated with reduced ventricle 
size measured by MRI after 3 days. However, only uroki-
nase was associated with improved behavioral outcome 
[117].
Thrombolytic agents in children with posthemorrhagic 
hydrocephalus
Pediatric clinical trials in the 1990s initially showed 
some promise for prevention of post-hemorrhagic 
hydrocephalus through use of several thrombo-
lytic agents. Premature infants with IVH (n  =  18 
vs. 39 controls, nonrandomized) were treated with 
intraventricular urokinase for 7 days; they were reported 
to have a lower requirement for shunting than historical 
controls (37 vs. 92 %) [118, 119]. In a pilot study, six pre-
mature infants with IVH, ventricular dilation, and head 
enlargement (>2 cm per week) despite diuretic therapy 
and serial lumbar punctures received intraventricu-
lar urokinase for 3  days. Although the intraventricular 
clot decreased in size and there were no apparent side 
effects, all infants required a shunt. The authors con-
cluded that late initiation of urokinase was ineffective 
in this situation [120]. Following the observation that 
CSF plasminogen levels were low in premature infants 
with IVH [121], Whitelaw and coworkers administered 
intraventricular bolus of recombinant tPA to 22 infants 
with post-hemorrhagic hydrocephalus; among the 21 
survivors, 12 did not require a shunt [122]. A phase 1 
clinical trial then showed that 17/23 survivors did not 
require a CSF shunt [123]. However, a multicenter ran-
domized trial of 70 infants showed that intraventricular 
tPA and CSF washing (drainage, irrigation, and fibrino-
lytic therapy; DRIFT) did not reduce shunt surgery or 
death and was potentially associated with secondary 
intraventricular hemorrhage [124]. Although the imme-
diate results did not look favorable, a 2-year follow-up 
of surviving children from the DRIFT trial indicated 
that treatment was associated with a reduction of severe 
cognitive disability [125], but this did not correlate with 
any improvement in brain volume measured by MRI 
[126].
During this same period, nine preterm infants received 
intraventricular infusion of streptokinase for 12–72  h 
without major adverse events [127]. A randomized case-
control trial conducted 1992–1994 included six infants 
who received intraventricular streptokinase for 4  days. 
Although fibrin degradation products were significantly 
elevated and blood clot reabsorption occurred after infu-
sion, there was no difference in the number of children 
who required shunting (3/5 survivors in each group); 
the authors concluded that they could “not recommend 
fibrinolytic intraventricular infusion as a routine treat-
ment” [128]. Another prospective case control trial of six 
treated and six untreated infants also led to the conclu-
sion that streptokinase should not be used in this situa-
tion [129]. In 1999, the authors of an excellent review 
of the five small case series published to that time con-
cluded, “While there is insufficient evidence to justify any 
claim that fibrinolytic therapy is safe and effective, there 
is also insufficient evidence to justify discarding this form 
of treatment as ineffective or unsafe” [130]. Systematic 
reviews of the randomized trials show no support for 
intraventricular streptokinase treatment after intraven-
tricular hemorrhage in premature infants [131].
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Thrombolytic agents in adults with posthemorrhagic 
hydrocephalus
Similar clinical approaches have been used with varied 
success in adults with hydrocephalus following IVH or 
subarachnoid hemorrhage. Among six adults with severe 
IVH who received intraventricular urokinase for 7 days, 
5/6 had a good or excellent outcome, while only two 
required shunting for hydrocephalus [132]. A small ran-
domized trial of adults with IVH showed a lower mor-
tality and slightly lower likelihood of need for shunt (3/9 
vs. 2/4), but a high incidence of very poor neurological 
outcome among survivors (7/10) [133]. A retrospective 
study of 14 adults with spontaneous IVH and hydroceph-
alus treated with intraventricular urokinase from 2002–
2005, suggested that the therapy was safe; in comparison 
to historical controls, it seemed to be associated with 
reduced mortality and reduced incidence of ventricular 
drain obstruction [134]. Wang advocated for intrathecal 
administration of urokinase to treat acute hydrocepha-
lus in adults [135]. A pilot experiment in adults with IVH 
showed that intraventricular tPA was associated with 
reduction of intraventricular blood and normalization of 
ventricular size within 1–2 days [136]. In an uncontrolled 
trial, adults with intracerebral hemorrhage and hydro-
cephalus exhibited rapid resolution of the hematoma 
when tPA was infused into the ventricle; compared to the 
historical controls, tPA infusion combined with lumbar 
drainage seemed to reduce the need for CSF shunting 
(33 vs. 3  %) [137, 138]. High dose tPA (4  mg tPA every 
12 h to a maximum cumulative dose of 20 mg tPA) was 
associated with more rapid clot resolution from the lat-
eral ventricles but not the third or fourth ventricles [139]. 
In 2007–2008, 41 subarachnoid hemorrhage patients 
received intraventricular tPA for 5–7  days. In compari-
son to historical controls, tPA recipients had fewer days 
in severe vasospasm and the incidence of hydrocephalus 
requiring shunt was also lower (18 vs. 43 %) [140]. A ran-
domized double blind trial testing the value of intraven-
tricular tPA for adults with IVH was underway in 2015 
[141]; interim analysis showed that the rate of rebleeding 
was not a major risk [142]. Unfortunately, the need for a 
shunt to treat hydrocephalus is not one of the planned 
outcome criteria.
Summary of blood clot lysis for hydrocephalus
In general, animal and human studies (both pediatric 
and adult) show that enzymatic blood clot lysis acceler-
ates the resolution of the blood collection, but offers no 
long-term protection against the development of hydro-
cephalus [143, 144]. Authors of a systematic review con-
cluded “intraventricular thrombolytic agents including 
tPA, urokinase, or streptokinase are not recommended 
as methods to reduce the need for shunt placement in 
premature infants with [posthemorrhagic hydrocepha-
lus” (high clinical certainty) [145]. Similarly, a meta-
analysis of trials on adult patients with aneurysmal IVH 
concluded “intraventricular rt-PA has no significant effi-
cacy on the long-term functional recovery” [146]. A more 
recent trial found that intraventricular tPA had no effect 
on the need for CSF shunt dependency or the functional 
outcome of adults with endovascular-treated aneurysmal 
SAH [147]. Recent data suggest that the sudden release 
of blood breakdown products by fibrinolysis might fail 
to protect against hydrocephalus because inflammation 
is increased by rapid blood clot lysis [148]. Neverthe-
less, there remains the possibility that tPA in children 
with posthemorrhagic hydrocephalus might offer some 
long-term benefits unrelated to the development of 
ventriculomegaly.
Experimental interference with inflammation in the 
meninges
There is a clear association between inflammation in the 
CSF pathways and subsequent development of hydro-
cephalus. Therefore, anti-inflammatory agents have been 
tested experimentally to prevent post-meningitis and 
post-hemorrhagic hydrocephalus. Rabbits with meningi-
tis caused by S. pneumoniae develop increased resistance 
to CSF outflow. If they are treated with methylpredniso-
lone within 1 day after the bacterial inoculation, CSF out-
flow is normalized, likely due to decreased inflammation 
[149]. Adult rabbits develop hydrocephalus following 
intraventricular blood injections repeated over a 2-week 
period. Those that received concurrent intramuscular 
methylprednisolone had significantly reduced severity of 
hydrocephalus, but intraventricular methylprednisolone 
caused ventricular enlargement in 35 % of rabbits [150]. 
A detailed study of post-hemorrhage fibrosis in the suba-
rachnoid compartment of dogs with autologous blood 
injection into the cisterna magna showed that intrathe-
cal dexamethasone did not significantly alter the fibrosis 
at 3 weeks or 3 months [151]; the ventricle size was not 
measured in these dogs.
Anti‑inflammatory agents in humans with meningitis
In humans, high quality randomized trials of corticoster-
oid therapy for acute bacterial meningitis show signifi-
cantly reduced hearing loss and neurological sequelae, 
although there are no specific data concerning develop-
ment of hydrocephalus [152]. A recent retrospective 
study of adults with bacterial meningitis suggests that 
increased brain ventricle size in the acute phase of bac-
terial meningitis is associated with increased mortality 
[153]. A meta-analysis of clinical trials using corticoster-
oids to treat tuberculosis meningitis indicated a marginal 
benefit with reduction of death and disabling residual 
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neurological deficit amongst survivors [154], but the 
likelihood of developing hydrocephalus was not changed 
[155, 156]. However, a recent randomized study of chil-
dren with tuberculous meningitis suggested that high 
dose prednisolone (4 mg/kg/day over 4 weeks vs. 2 mg/
kg/day) might be associated with increased risk of hydro-
cephalus [157]. A rare congenital autoimmune disease 
called chronic infantile neurologic, cutaneous, articular 
(CINCA) syndrome is characterized by neonatal-onset 
chronic meningitis; a single child who developed hydro-
cephalus was successfully managed with anakinra, a 
recombinant interleukin-1-receptor antagonist [158].
Role of transforming growth factor beta in the development 
of subarachnoid fibrosis
Considering the marginal successes of blood lysis and 
anti-inflammatory agents for managing hydrocephalus, 
a more targeted molecular approach seems worth con-
sidering. Transforming growth factor beta (TGF-β) is 
a growth factor released from platelets at sites of blood 
clotting whereupon it regulates proliferation of fibro-
blasts (and other cell types), as well as the synthesis of 
extracellular matrix proteins. In 1994, high levels of TGF-
β1 in the CSF of adults with subarachnoid hemorrhage 
were shown to be associated with enlargement of the cer-
ebral ventricles [159, 160]. A similar association was later 
shown in premature infants with IVH [161, 162]. How-
ever, it must be noted that recent data obtained from a 
CSF assay study failed to support a critical role for TGF 
β1 and TGF β2 in the development of posthemorrhagic 
hydrocephalus in adults [163].
In neonatal rats with intraventricular blood injection, 
TGF-β1, TGF-β2, and TGF-β3 are increased, although 
only the latter was associated with enlarged ventricles 
and only TGF-β1 was restricted to the meninges. This 
was accompanied by deposition of fibronectin, laminin, 
and vitronectin in brain tissue [164]. In animal experi-
ments, injection of TGF-β1 into the subarachnoid com-
partment of 10-day old mice caused hydrocephalus [165, 
166] as a consequence of progressive fibrosis in the lep-
tomeninges [167]. Intracerebroventricular infusion of 
recombinant human hepatocyte growth factor, which 
antagonizes the fibrosis-inducing effect of TGF-β1, for 
7 or 14 days, improved the memory, ventricle size, CSF 
flow, and meningeal fibrosis in mice with TGF-β1 injec-
tion-induced hydrocephalus [168].
Transgenic mice with TGF-β1 overexpression linked 
to the glial fibrillary acidic protein (GFAP) promoter in 
astrocytes develop hydrocephalus with no obstructions 
in the ventricular system [169, 170]. These mice have 
increased cellularity and obstruction to CSF flow in the 
subarachnoid compartment, and they develop enlarged 
ventricles beginning at postgestation day 15 [171–173].
Interference with the TGF-β1 pathway has been 
explored as a means to treat or prevent experimental 
hydrocephalus. Seven-day-old rats with post-IVH hydro-
cephalus were randomized to receive the drugs pirfe-
nidone or losartan, which have been shown to reduce 
TGF-β expression and decrease inflammatory fibrosis in 
lungs and other organs. After 14 days treatment, neither 
drug had a beneficial effect on ventricle size or behav-
ior [174]. Infusion of thrombin into the subarachnoid 
compartment of adult rats mimics some of the changes 
that occur after subarachnoid hemorrhage, including 
increased expression of TGF-β1 and meningeal collagen 
accumulation. Administration of the TGF-β1 inhibitor 
SB-431542 into the cisterna magna prior to thrombin 
injection blocked the collagen accumulation at 10 and 
20 days [175].
Three-week old rats received subarachnoid injections 
of kaolin with or without infusions of decorin, a small 
proteoglycan that can bind TGF-β1. There was good evi-
dence that the decorin-treated rats had reduced inflam-
mation and fibrosis in the subarachnoid compartment 
[176]. However, the fact that treatment began before the 
onset of hydrocephalus and the large number of exclu-
sions from the decorin group makes this an interest-
ing proof-of-principle only. A follow-up experiment by 
the same group is planned with delayed (1 week) initia-
tion of decorin treatment (personal communication; Dr. 
P. McAllister September 2015). Another group used a 
subarachnoid model in 6-week-old rats; the rats received 
intracisternal injection of decorin immediately before 
blood injection followed by intracerebroventricular injec-
tion of decorin 10  days later. The treated rats convinc-
ingly had inhibited up-regulation of TGF-β1, reduced 
collagen, reduced ventricle size, and improved cognitive 
outcome [177].
The TGF-β and Wnt signaling pathways converge 
through the Smad/YAP complex, which translocates to 
the nucleus to activate various genes related to fibrosis 
[178]. Ventricle size and reactive astroglial changes were 
measured in adult rats following injection of kaolin into 
the lateral ventricle. If sFRP-1, a Wnt inhibitor, was added 
to the kaolin, the ventricle enlargement was less severe 
and the GFAP expression was reduced in periventricu-
lar regions of unspecified location [179]. Although not 
measured directly, inhibition of the Wnt signaling cas-
cade might alleviate development of hydrocephalus by 
reducing fibrosis.
Young adult mice with kaolin-induced hydrocepha-
lus were maintained on tap water or deuterium water 
beginning 7 days prior to kaolin. The stated rationale was 
previous evidence that deuterium could inhibit cell pro-
liferation and fibrosis in vitro. After 4 weeks, the treated 
rats had ventricles of normal size, reduced collagen on 
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extracted tissue sections, and reduced TGF-β1 immu-
noreactivity in posterior fossa compared to untreated 
hydrocephalic rats [180]. This demonstration of a seem-
ingly miraculous treatment had several shortcomings; 
the most important being the failure to demonstrate 
that kaolin was actually delivered into the subarachnoid 
compartment. Finally, 7-day rats with periventricular 
hemorrhage induced by intracerebral injection of col-
lagenase received the TGF receptor 1 inhibitor SD208 
daily for 3 days, beginning 1 h or 3 days after collagenase 
injection. SD208 reduced the adverse behavioral effects, 
weight loss, and associated brain injury [181]. However, 
considering that the ventricular enlargement was uni-
lateral and apparently due to brain atrophy, this experi-
ment should not be considered evidence for treatment of 
hydrocephalus.
In summary, antagonism of the TGF-β1 pathway has 
excellent rationale for prevention of post-hemorrhagic 
or post-meningitis hydrocephalus, but more preclinical 
experimentation is required.
Deferoxamine for preventing fibrosis
Deferoxamine is a chelating agent that binds free ferric 
iron (Fe3+). It is used effectively in a variety of diseases 
associated with blood breakdown; it can prevent fibro-
sis by attenuating oxidative stress and the subsequent 
inflammatory cascade [182]. There are promising experi-
mental data for treatment of intracerebral hemorrhage 
[183]. Ventricular enlargement was studied after fluid 
percussion brain injury in adult rats. Deferoxamine was 
administered beginning 2  h after injury and the brains 
were studied at 1 day. Deferoxamine was associated with 
normalized ventricle size and upregulation of heme oxy-
genase 1 [184]. In another lab, young adult rats received 
unilateral injection of autologous whole blood or ferric 
chloride (FeCl3) into the lateral ventricle. Intraperitoneal 
deferoxamine was administered beginning immediately 
afterward and then for 7 days; the brains were examined 
at 1 or 4 weeks. Blood or FeCl3 caused enlarged ventricles 
and deferoxamine treatment prevented ventricle enlarge-
ment [185, 186]. The authors discussed neuroprotective 
properties and anti-fibrotic properties of the agent, but 
did not directly study the meningeal compartment.
Reversing accumulation of extracellular matrix molecules 
in the subarachnoid compartment
As with any wound healing processes, hyaluronic acid 
and a variety of proteoglycans are produced in the first 
few days after a hemorrhagic or inflammatory process. 
Several weeks are necessary before collagen, which is 
more permanent, is produced [187, 188]. These fibrosis-
associated molecules seemed a reasonable target, albeit a 
late one, for modulation in hydrocephalus. A variety of 
purified enzymes, including the matrix metalloprotein-
ases (MMP), are capable of degrading a variety of extra-
cellular matrix molecules.
In a rabbit model of IVH, ventricular enlargement 
occurs. Single intracerebroventricular injection of chon-
droitinase ABC, which digests a variety of proteoglycans, 
did not reduce the ventriculomegaly, although it should 
be noted that the subarachnoid compartment was not 
studied directly [189].
In a few small case series, animal-derived hyaluroni-
dase was administered intrathecally on a weekly basis 
for several weeks to children with tuberculous menin-
gitis and hydrocephalus. One of the earliest trials sug-
gested that hyaluronidase was superior to shunt surgery 
[190]. A later trial showed improved level of conscious-
ness but no overall improvement in comparison to CSF 
shunting [191]. One report claimed that hyaluronidase 
offered mild transient benefit in three children with mye-
lomeningocele [192]. However, the largest published trial 
showed that hyaluronidase was associated with reduced 
intracranial pressure but no change in ventricle size in 
12/17 children with tuberculosis-associated hydrocepha-
lus [193]; it is considered of historical interest only [194].
The MMP are a family of diverse enzymes capable of 
degrading a variety of extracellular matrix molecules. 
In experimental hydrocephalus, adult rats had elevated 
MMP9 in the CSF after intraventricular kaolin injection 
[195] while transgenic mice with TGF-β overexpression 
have reduced MMP9 mRNA and activity [196]. MMPs 
were assayed in the CSF of 13 premature children with 
posthemorrhagic hydrocephalus, 10 infants with non-
hemorrhagic hydrocephalus, and 10 controls. Pro-MMP9 
was found to be elevated in the CSF in 9/13 infants that 
did not require a shunt and the authors speculated that 
modulation of MMP9 activity might be a therapeutic 
strategy worth testing [197, 198]. However, inspection of 
their data shows that two children with very high levels 
skewed the MMP9 level.
Cerebral blood flow and pulsation in hydrocephalus
Diminished regional blood flow, particularly in the cer-
ebral white matter, is well documented in pediatric and 
adult hydrocephalus [199, 200]. It is not entirely clear 
if this is a purely mechanical phenomenon that results 
from distorted or compressed blood vessels, or if there 
is a dysregulation due to altered innervation or local cell 
interactions. Regardless of the cause, hypoxia likely con-
tributes to the pathogenesis of axon damage [201, 202]. 
Many adults with NPH have arterial hypertension and 
cerebrovascular disease [203, 204]. These epidemiologic 
data suggest that pre-existing vascular disease can aggra-
vate the brain dysfunction associated with hydrocephalus 
or that the abnormal blood pressure can contribute to 
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the development of ventriculomegaly. The role of vascu-
lar pulsations as mechanical contributor to ventricular 
enlargement is currently of great interest [205, 206]. A 
seldom-cited case report of an infant with hydrocephalus 
suggested that bilateral common carotid artery ligation 
was associated with reduced intracranial pulsation and 
stabilization of head size [207].
Vasoactive drugs in experimental hydrocephalus
Using the 3-week rat model of kaolin-induced hydro-
cephalus we demonstrated several aspects of the axonal 
damage that suggested a possible role for activation 
of proteolytic enzymes by intracellular calcium [208]. 
Based on that information, hydrocephalic rats were 
treated by continuous administration of the calcium 
channel blocker nimodipine for 2  weeks, beginning 
2  weeks after induction of hydrocephalus (i.e. begin-
ning at 5  weeks age). Nimodipine treatment prevented 
the declines in motor and cognitive behavior that were 
observed in untreated control rats, and although the 
degree of ventricular enlargement was equal, the corpus 
callosum was thicker in the treated rats [209]. We later 
showed that Mg++ (delivered as MgSO4), a Ca++ com-
petitor, had a similar but weaker protective effect [210]. 
However, when nimodipine or Mg++ was administered 
to 1-week rats, there was no protective effect and the 
side effects were more substantial [211]. Recent experi-
ments from our lab showed that both agents, at the doses 
that were protective, have significant vasoactive effects 
in rats; these include decreased systemic arterial blood 
pressure, decreased cerebral perfusion and intracere-
bral pulse pressure, but no change in CBF (unpublished 
work; Shulyakov and Del Bigio, in preparation). We went 
on to test MgSO4 in a ferret model of hydrocephalus 
[212]; two-week ferrets received kaolin injections and 
beginning 2  weeks later received MgSO4 by parenteral 
injections. Although they had significant side effects 
(lethargy), there was no evidence for protection at the 
behavioral, structural, or biochemical level (Di Curzio, 
Turner-Brannen, Mao, Del Bigio; manuscript submitted). 
We are planning a ferret experiment with nimodipine is 
planned to determine if the protection is reproducible in 
a gyrencephalic animal with hydrocephalus.
Vasoactive drugs in humans with hydrocephalus
One group treated 18 hydrocephalic infants with oral 
isosorbide dinitrate, a nitrate vasodilator (8  mg/kg/day; 
for 1–25  months, median 3  months) [213]; the authors 
seem to have mistakenly equated this drug with the 
osmotic agent isosorbide. They considered the treatment 
useful because only 2/10 posthemorrhagic cases required 
shunting (versus 5/5 myelomeningocele cases).
Eight adults with NPH underwent blood pressure 
monitoring during administration of the calcium chan-
nel blocker nimodipine, which is commonly used for 
treatment of hypertension. Four hours after nimodipine, 
the mean arterial blood pressure was lower, the ICP was 
slightly higher, and overall there was no change in cer-
ebral perfusion pressure (estimated from the arterio-
venous oxygen difference) [214]. The antihypertensive 
agent ketanserin was administered to eight patients with 
NPH as a single bolus; it caused a decrease in blood pres-
sure without altering ICP of CBF [215]. These studies 
prove nothing in the context of managing hydrocephalus, 
although it does suggest that nimodipine should be safe.
Greitz suggested that selective venous constriction, 
for example using dihydroergotamine, might modulate 
the intravascular dynamics, although it should be noted 
that his logic was not entirely clear (“Venous constric-
tion would result in dilatation of the venous side of the 
capillary, decrease of the microvascular resistance, open-
ing up of the microcirculation and reduced intracranial 
pressure”) [216]. This approach has never been tested 
experimentally. Dihydroergotamine causes contraction 
of isolated human cortical arteries and veins [217], but it 
has no effect on CBF in normal adults [218]. It can reduce 
intracranial pressure in patients with traumatic brain 
injury [219], while it may be associated with increased 
intracranial pressure in brain tumor patients, possibly 
due to loss of autoregulation [220]. Based on these con-
tradictory data, pursuing dihydroergotamine as a therapy 
for hydrocephalus seems unwise.
Vascular endothelial growth factor (VEGF) in hydrocephalus
VEGF is one of the best-known promoters of angiogen-
esis and vascular survival. It also plays a role in vascu-
lar permeability factor, and it may also provide direct 
trophic support to neurons [221]. Because of the known 
vascular and CBF alterations in hydrocephalic brains, 
VEGF is a logical target for investigation. VEGF func-
tion is mediated through specific receptors in the brain 
[222]. In a dog model of chronic hydrocephalus, signifi-
cant decreases in frontal cortex VEGFR-2 were reported; 
VEGF was not altered in tissue, but it increased in the 
CSF [223]. In the same dogs, VEGFR-2 increased in the 
hippocampus; this corresponded to increased blood ves-
sel density, which was not seen in frontal cerebrum [224]. 
This is of interest because typically the hippocampus sus-
tains only minimal direct damage in hydrocephalic brains 
(although there is considerable damage to the connecting 
pathways) [225]. The authors suggested that modulation 
of VEGF and its receptor might be a useful therapy for 
the chronic brain hypoxia that occurs in hydrocepha-
lus [226]. Moderate arm exercise in adults with chronic 
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hydrocephalus was associated with elevated VEGF in the 
CSF [227].
In contradiction to the potential protective function 
of VEGF, another research group reported increased 
CSF levels of VEGF in children and young adults with 
hydrocephalus. They then infused VEGF into the cer-
ebral ventricles of non-hydrocephalic rats and found 
that the ventricles were enlarged. Simultaneous infusion 
of bevacizumab, an antagonist of VEGF, prevented this 
enlargement [228]. The authors devised an extremely 
complicated postulate in which the VEGF interacts with 
VEGFR-2 on ependymal cells leading to dysfunction of 
fluid regulation and ultimately to hydrocephalus [229].
Thus, we have a situation where one group of inves-
tigators suggests that VEGF/VEGFR-2 alterations are 
secondary to hydrocephalus and represent a benefi-
cial adaptation to chronic hypoxia, while another group 
claims that VEGF causes ventriculomegaly. This is a sub-
ject that needs clarification before drug interventions are 
tested in humans.
Brain protection in hydrocephalus
Hydrocephalus is associated with gradual destruction of 
periventricular white matter leading to a disconnection 
syndrome. In the circumstance of the immature brain, 
hydrocephalus also interferes with developmental pro-
cesses including cell genesis and myelination [201, 230]. 
In the situation of progressive ventricular enlargement 
wherein shunt therapy is likely necessary, drugs might 
be used to protect the brain temporarily prior to shunt-
ing. Considering the overlap in pathophysiology between 
hydrocephalus, stroke, and trauma, it is anticipated that 
candidates from the latter two diseases should be consid-
ered for protecting the hydrocephalic brain. In neonatal 
hypoxic-ischemic brain injury, a variety of potential early 
therapeutics have broadly been categorized into anti-oxi-
dative, anti-inflammatory, anti-apoptotic, and anti-exci-
totoxic mechanisms, with melatonin and erythropoietin 
covering multiple mechanisms [231]. Additional file  1: 
Table 1 summarizes the experiments conducted to date in 
hydrocephalic animals including the rationale, strengths, 
and weaknesses.
Anti‑inflammatory interventions and microglia
Microglial and astroglial activation occurs in animals 
and humans with hydrocephalus [232, 233]. Microglial 
response is reported to contribute to brain damage in 
many disorders [234], although microglial activation 
might also have beneficial effects [235, 236]. Neverthe-
less, until the damage-benefit balance related to micro-
glia is settled, anti-inflammatory interventions could be 
considered in the treatment of hydrocephalus.
Minocycline is a semi-synthetic tetracycline deriva-
tive with anti-inflammatory properties. It appears to be 
protective in a range of animal neurological disorders as 
well as human stroke [237, 238]. Intraperitoneal admin-
istration of minocycline to H-Tx rats with congenital 
hydrocephalus from postnatal day 15 to day 21 was asso-
ciated with increased cortical thickness (ventricle size 
was not measured) and reduced cerebral immunolabe-
ling for Iba-1 (a microglial marker) and GFAP (an astro-
cyte marker) [239]. Young adult rats with kaolin-induced 
hydrocephalus were given minocycline from day 15 to 
day 21 after kaolin. Treated rats had reduced progression 
of the ventricle size and reduced Iba-1 and GFAP in the 
brain [240]. In 7-day-old rats that had intracerebral hem-
orrhage induced with collagenase injection, minocycline 
treatment administered daily for 5 days beginning imme-
diately was also associated with improved behavioral out-
come and less severe ventricular enlargement at 28 days 
[241]. Although minocycline seems promising, the main 
side effect of tooth discoloration must be considered in 
the pediatric population [242].
Transgenic mice with hydrocephalus secondary to 
TGF-β overexpression were administered the non-steroi-
dal anti-inflammatory agents ibuprofen or pioglitazone, a 
peroxisome proliferator-activated receptor-γ agonist, from 
2 to 4 months age. Although both suppressed activation of 
microglia (based upon cellular hypertrophy), neither drug 
had an effect on thioflavin S staining of amyloid in cerebral 
blood vessels and pioglitazone aggravated the ventriculo-
megaly (ventricle size was not measured in the ibuprofen 
recipients) [243]. It is not clear, however, that thioflavin S 
staining is a good outcome measure in young rats.
Adult rabbits were treated 1  day after intracisternal 
kaolin injection with a single dose of infliximab, a mono-
clonal antibody that binds to tumor necrosis factor-alpha 
(TNF), which is an important mediator of inflammatory 
responses that is produced by microglia. After 2 weeks, 
blood and CSF levels of TNF were reduced in treated rab-
bits, although ICP was not different between the groups. 
After sacrifice the only histological evaluation was ter-
minal deoxynucleotidyl transferase-mediated dUTP nick 
end labeling (TUNEL) in the optic disc, optic radiation, 
and the lateral geniculate body; treated rabbits had fewer 
labeled cells with microglial morphology in the two lat-
ter locations [244]. Unfortunately, this experiment is very 
difficult to interpret because the ventricle size was not 
measured at any time and the significance of microglial 
death in the optic pathway is of unknown significance.
Antioxidative interventions
Numerous animal experiments and investigations of 
human CSF indicate that hydrocephalus is associated 
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with oxidative and nitrosylative cell responses and dam-
age, likely secondary to the chronic hypoxia [245, 246]. 
In 3-week rats with kaolin-induced hydrocephalus, epi-
gallocatechin gallate derived from green tea and N-ace-
tylcystein [sic] were both shown to reduce brain tissue 
malondialdehyde, one of the end products of lipid per-
oxidation [247, 248]. However, the biochemical assay 
was the sole outcome parameter (ventricle size was not 
measured) so the value of these interventions is unclear. 
Two-week old rats received daily melatonin injections 
for 4  weeks beginning immediately after intracisternal 
kaolin injection. Nitric oxide content was not signifi-
cantly changed and glutathione was almost normalized 
in the choroid plexus of hydrocephalic animals [249]. 
However, ventricle size was assessed only qualitatively 
by inspection of the midsagittal slice, and the histologic 
interpretation of the choroid plexus is not convincing. 
Beginning 2  weeks after kaolin injection into 3-week-
old rats, we administered an oral mixture of antioxi-
dants (alpha-tocopherol, L-ascorbic acid, coenzyme 
Q10, reduced glutathione, and reduced lipoic acid) for 
2 weeks. We detected no therapeutic effect on the analy-
sis of behavior, brain structure, or biochemical content; 
of uncertain significance, we observed that the canola 
oil carrier normalized anti-oxidant capacity of the brain 
tissue [250]. Catechin polyphenols present in the leaves 
of Camellia sinensis are potent antioxidants. Seven-day-
old rats were injected with kaolin and received extracts 
of C. sinensis daily beginning 2 days later. Although there 
was no behavioral protection and the ventricle size was 
not measured, treated rats had thicker corpus callosum 
at 10 days age (but not 21 days age) and had a significant 
reduction in the reactive astrocytes [251]. Using a similar 
protocol, the same group is currently doing a study with 
edaravone (30 mg/kg; Luiza da Silva Lopes, unpublished 
work), which is a free radical scavenger that appears to 
have some benefit in adults with acute ischemic stroke 
[252]. Adult rats received intraventricular injection of 
autologous whole blood; those that received simulta-
neous edaravone had less brain edema and less tissue 
malondialdehyde on day 1 and improved memory on day 
28 [253].
Neuron and axon protection
Periventricular axons sustain most of the damage in 
hydrocephalic brains with secondary retrograde degen-
erative changes in some neuron populations [201, 230]. 
Memantine, a non-competitive NMDA receptor antago-
nist, protects neurons and axons in a variety of animal 
models [254]. One day after kaolin injection, 3-week old 
rats began receiving memantine daily for 2  weeks. Low 
resolution MRI verified the presence of hydrocepha-
lus at the end of the study. Histologic counts indicated 
reduced neurons in the hippocampus of hydrocephalic 
rats, and partial recovery in the CA1 and CA2 (but not 
CA3) sectors of memantine-treated rats [255]. It should 
be noted that in other rodent hydrocephalus studies, hip-
pocampal neurons are reported to be spared or show 
various secondary abnormalities due to deafferentation 
[256–258]. Memantine or an herbal medicine, Morinda 
citrifolia, were given to adult rabbits for 2 weeks begin-
ning immediately after intracisternal kaolin injection; 
brain tissue around the fourth ventricle was analyzed by 
immunostaining for activated caspase-3 as a measure of 
cell death. The authors reported that memantine aggra-
vated cell death while the herbal therapy was neutral 
with respect to hydrocephalus [259]. This experiment is 
flawed because the fourth ventricle size was not reported, 
the presence of kaolin in the immediate vicinity was not 
documented, and the caspase 3 immunostaining is not 
convincing. The lead author’s group is planning to test 
memantine in young hydrocephalic rats and measure 
behavioral, structural, and biochemical outcomes (exper-
iment scheduled for early 2016).
Based on prior reports of axon protection in traumatic 
brain injury models, we treated 3-week-old hydroce-
phalic rats with tacrolimus, cyclosporine A, or calpain 
inhibitor I; there was no statistically significant protec-
tion in regard to behavior, brain structure or brain com-
position in any of the experiments [260]. In the same 
model system, we found no evidence for protection using 
the sodium channel-blocking agents mexiletine and rilu-
zole [261].
Cerebral stimulants
Considerable experimental work [201] and many assays 
of human CSF [262] have showed that the monoamine 
neurotransmitter systems are disturbed in hydrocepha-
lus. These correlate with some of the functional distur-
bances seen in hydrocephalic patients. A monoamine 
oxidase inhibitor, bifemelane, used as an antidepressant 
and “cerebral metabolic activator” tended to normalize 
norepinephrine and serotonin levels (albeit with wide 
variance) in the striatum and cerebral cortex of young 
adult rats with kaolin-induced hydrocephalus [263]. Sev-
eral case reports of hydrocephalic patients treated with 
a variety of similar agents have been published. Methyl-
phenidate, which is widely used for treatment of atten-
tion deficit hyperactivity disorder and which acts by 
blocking the dopamine and norepinephrine transporters, 
was administered to a single NPH patient (20  mg) in a 
double blind cross-over trial after she had been shunted; 
the drug as associated with improved cognitive perfor-
mance and reduced apathy [264]. In another case report, 
a single NPH patient with depression responded well to 
twice-daily oral doses of 10  mg methylphenidate [265]. 
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In two separate reports, two people with hydrocepha-
lus and akinetic mutism (that persisted after shunt revi-
sion) responded well to bromocriptine and ephedrine 
[266, 267]; the former is a dopamine agonist and the lat-
ter is a sympathomimetic amine that increases the activ-
ity of norepinephrine. Finally, an unshunted 19 year-old 
with severe hydrocephalus and aggressive self-injurious 
behavior responded well to trazodone (200  mg/day) 
[268], which is an antidepressant of the serotonin antago-
nist and reuptake inhibitor class.
Although entirely anecdotal, this avenue of therapy 
seems open for further investigation.
Protection of the developing brain in early‑onset 
hydrocephalus
A poorly studied aspect of hydrocephalus-associated 
brain damage is that due to disruption of the perive-
ntricular germinal matrix [269], which is the zone of 
proliferating cells that gives rise to neuron and glial pre-
cursors during human fetal life (or during the postnatal 
life of extremely premature infants).
In an elegant experiment, embryonic mice received 
injections of blood plasma, blood serum, or lysophospha-
tidic acid (LPA; which is a normal component of blood 
plasma) into the lateral ventricle on in utero day 13.5. 
These (but not red blood cells) caused severe hydrocepha-
lus, which was progressive for at least 30 days after birth. 
The authors identified damage to the germinal cells along 
the ventricle wall and occlusion of the third ventricle as 
the cause of hydrocephalus. Pharmacological blockade 
with Ki16425, a receptor antagonist of LPA1 and LPA3, 
prevented the hydrocephalus [270]. The pathologic fea-
tures in this mouse model resemble those in human fetal 
hydrocephalus caused by cryptic hemorrhage [271] and 
prematurity associated germinal matrix hemorrhage [272]. 
LPA from blood is postulated to disrupt the germinal zone. 
More experimental work is needed to determine if this can 
be developed into a practical clinical therapy for prema-
ture infants with intraventricular hemorrhage [273].
The H-Tx rat has inherited hydrocephalus that is caused 
by aqueduct stenosis, which develops around 18 days ges-
tation [274]. The genetic cause of this partially penetrant 
disorder is not yet known [275]. Maternal administration 
(subcutaneous) of folic acid aggravates the incidence of 
hydrocephalus while a mixture of folinic acid and tetrahy-
drofolate significantly reduces the incidence of hydroceph-
alus. Various experiments led to the conclusion that folate 
imbalance is responsible for the defects that lead to this 
form of early-onset hydrocephalus [276].
Cell transplantation
Although cell transplantation is not, strictly speaking, a 
non-surgical intervention, it is mentioned here because 
it is not a shunt intervention. In one experiment, the 
serotoninergic innervation was destroyed by injec-
tion of the toxin 5,7-dehydroxytriptamine into brains 
of young adult rats, which were then rendered hydroce-
phalic by injection of kaolin. After 2  weeks, brain cells 
from 14-day gestation rat embryos were transplanted 
into the hippocampus; transplanted cells were detected 
by immunohistochemistry 4 weeks later. In the few ani-
mals studied, surviving cells were identified; the authors 
simply concluded that the hydrocephalic brain is capable 
of accepting transplanted cells [277]. Intracerebral trans-
plantation of human umbilical cord mesenchymal stem 
cells was reported in a pair of experiments. Four-day-old 
rats received bilateral injections of maternal blood into 
the lateral ventricles, 2 days later MRI was used to evalu-
ate the ventricle size, and then rats were randomized to 
receive intraventricular stem cells or fibroblasts or vehi-
cle. By 32 days age, stem cell recipients (but not those in 
the other groups) had attenuation of the ventricle size as 
well as improved behavior, reduced brain cell death, and 
reduced reactive astroglial change. Reduced quantity 
of periventricular microglia and reduced levels of pro-
inflammatory cytokines in the CSF and periventricular 
brain tissue led the authors to speculate that the mesen-
chymal stem cells reduced the hemorrhage-associated 
inflammation [278, 279], but this mechanism was not 
proved.
Conclusions
Hydrocephalus can be modeled in a wide range of ani-
mal species by injection of blood or kaolin into the CSF 
pathway, or by genetic manipulation [280]. Many of the 
models reflect the pathogenesis of hydrocephalus in 
human disorders. Several pharmacologic interventions 
appear to alleviate experimental hydrocephalus over rela-
tively short terms (i.e. weeks). Manipulation of water bal-
ance or CSF production by osmotic agents or ion channel 
antagonists also works transiently in humans. However, 
poorly controlled clinical studies and rare randomized 
trials show no overall benefit in the management of 
hydrocephalic patients. CBF response to acetazolamide 
challenge appears to have a role as a test for predicting 
shunt responsiveness in adults with NPH. There may 
be some opportunity for revisiting acetazolamide with 
proper dosing in accordance with its pharmacodynamics 
or development of agents that more selectively inhibit the 
choroid plexus.
Fibrinolytic agents that hasten the resolution of intra-
ventricular or subarachnoid blood collections do not 
clearly prevent the development of hydrocephalus in 
infants or adults. A European survey conducted in 2010 
indicated that there remains no consensus on the treat-
ment of infants with post hemorrhagic hydrocephalus; 
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only a small minority of neonatal care centers (6 %) was 
using fibrinolytic agents [281, 282]. Nevertheless, attenu-
ation of the iron toxicity (e.g. with deferoxamine) remains 
a potential target for reduction of the inflammatory and 
fibrotic reactions that block the CSF pathways after hem-
orrhage or meningitis. Targeted molecular manipula-
tion of the cellular mechanisms that lead to fibrosis in 
the leptomeninges (e.g. of TGF beta or pathways) might 
reduce obstruction to CSF flow through the subarach-
noid compartment, thereby preventing the development 
of hydrocephalus. Once the reactive extracellular matrix 
molecules are established in the subarachnoid compart-
ment, opportunities for digesting them seem limited.
Modulation of cerebral blood flow through vasoac-
tive agents also seems sensible, but this work remains in 
the preclinical status. Use of cerebral stimulants to aug-
ment compromised neurotransmitter systems is wide 
open for investigation. Brain protection is also in the 
early preclinical stages. Minocycline, which acts through 
multiple molecular routes [283], shows early promise. 
Anti-oxidant therapies have typically been unsuccessful, 
or the experiments are limited by drug administration in 
a clinically irrelevant manner or by inadequate outcome 
analysis.
Perhaps surprising, some multifunctional agents that 
have progressed into clinical trials have not been tested in 
hydrocephalus. Erythropoietin is a multifunctional mol-
ecule that is neuroprotective through its receptor (EpoR) 
and has systemic anti-inflammatory and angiogenic 
effects that can reduce brain injury. Several randomized 
trials are underway to determine its effect in preterm 
infants [284]. A retrospective analysis of extremely low 
birth weight infants treated with erythropoietin from 
1993 to 1998 indicated that hydrocephalus requiring 
shunting occurred in 4.5 % of treated survivors and 7.0 % 
of controls [285]. Other less well-studied agents (e.g. gin-
senoside [286]) also deserve attention.
Brain protection has been the Holy Grail for thousands 
of stroke and trauma experiments, and has almost always 
failed in translation to the clinical setting [13, 287–291]. 
Those interested in hydrocephalus must take great care 
in the preclinical development of proposed therapies. 
Based upon recommendations from the stroke and brain 
trauma literature [11–13], we must design robust experi-
ments including the following considerations: (a) the 
chosen animal model of hydrocephalus must have valid-
ity with respect to the human situation of interest (rodent 
models may be useful for screening but verification 
should be performed in a larger animal with gyrence-
phalic brain and voluminous white matter); (b) ventricle 
size should be measured before and after the intervention 
(preferably using in  vivo imaging); (c) drug assignments 
should be randomized or organized to ensure that groups 
are comparable; (d) evaluations must be conducted by 
blinded investigators; (e) the primary outcome measures 
must be pre-determined; (f ) outcome measures should 
include a combination of morphological, behavioral, and 
biochemical parameters; (g) drug administration should 
mimic the timing, delivery route, and dosage feasible in 
humans; careful attention must be paid to the pharma-
cokinetic properties of agents to be tested to ensure an 
optimal response; blood brain barrier permeability must 
also be considered because, in general, the blood brain 
barrier is intact in the hydrocephalic brain [292]; (h) drug 
administration should not involve pre-ventriculomegaly 
administration except as proof-of-principle (unless the 
agent is being used to prevent hydrocephalus in high risk 
situations); (i) statistical assessment of outcomes should 
use appropriate corrections for multiple comparisons; (j) 
candidate drugs should work in multiple species and in 
multiple laboratories before testing in humans. Unlike 
stroke and trauma in which most of the damage is initi-
ated within the first few minutes, hydrocephalus is pro-
gressive; therefore, in the absence of a shunt intervention 
or in the circumstance of chronic static hydrocephalus, 
long-term outcomes may not be possible.
Despite over 5 decades research, no compelling non-
surgical therapies have been developed for hydrocepha-
lus. However, there remain several targets for prevention 
of hydrocephalus or as a complement to shunting. Ulti-
mately, high quality preclinical experiments should be 
used to design clinical trials for premature neonates and 
adults in which ventricle size and need for shunting are 
included among the main outcome measures. Complex 
experiments testing augmented recovery or regenera-
tion after shunting have not been attempted, but may 
be needed to address the clinical fact that some patients 
ultimately do need a shunt.
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